NR
VRTX icon

Newfound Research’s Vertex Pharmaceuticals VRTX Stock Holding History

Newfound Research’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-489
Closed -$128K – 152
2022
Q1 		$128K Sell
489
-201
-29% -$47.7K 0.17% 70
2021
Q4 		$152K Buy
690
+113
+20% +$22K 0.18% 48
2021
Q3 		$105K Buy
577
+188
+48% +$36.7K 0.17% 62
2021
Q2 		$78K Buy
389
+37
+11% +$7.74K 0.15% 84
2021
Q1 		$76K Buy
352
+172
+96% +$37.8K 0.18% 62
2020
Q4 		$43K Buy
180
+75
+71% +$17.2K 0.11% 119
2020
Q3 		$29K Buy
+105
New +$29K 0.08% 91

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Newfound Research's VRTX Position: Q2 2022 in Review

Newfound Research sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 489 shares — an estimated $128K sold.

Newfound Research first reported a position in VRTX in Q3 2020 and held it in 7 quarters. The position peaked at $152K in Q4 2021. 1,107 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Newfound Research reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Newfound Research sold 489 Vertex Pharmaceuticals shares in Q2 2022, an estimated $128K.
  • Newfound Research first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 7 quarters.
  • Newfound Research's Vertex Pharmaceuticals position peaked at $152K in Q4 2021.
  • 1,107 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Newfound Research's 13F filing for Q2 2022, filed 15 Jul 2022.